7 completed, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 11 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 7, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow imetelstat: new trials by email Literature Review of imetelstat trials Research Report on imetelstat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms Imetelstat - Phase II, Imetelstat | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2027-04-08 | 2026-11-12 |
| Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy Imetelstat sodium - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Completed | GCP-Service International West GmbH | 46 | 2023-06-05 | 2026-10-02 |
| Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Imetelstat Sodium, Placebo - Myelodysplastic Syndromes | Phase 2 / Phase 3 | Active not recruiting | Geron Corporation | 289 | 2016-01-12 | 2026-07-17 |
| Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg - Myelofibrosis | Phase 2 | Completed | Geron Corporation | 107 | 2015-08-28 | 2021-09-14 |
| Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Imetelstat Sodium, Laboratory Biomarker Analysis - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma | Phase 2 | Withdrawn | Children's Oncology Group | 2014-06-30 | 2018-08-07 | |
| Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors imetelstat sodium - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 2 | Terminated | Pediatric Brain Tumor Consortium | 43 | 2013-03-01 | 2018-07-20 |
| Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis Imetelstat - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Completed | Geron Corporation | 80 | 2012-10-29 | 2021-09-21 |
| Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Imetelstat - Essential Thrombocythemia, Polycythemia Vera | Phase 2 | Completed | Geron Corporation | 20 | 2010-12-01 | 2016-01-26 |
| Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma Imetelstat (7.5 mg/kg), lenalidomide standard of care, Imetelstat (9.4 mg/kg) - Multiple Myeloma | Phase 2 | Completed | Geron Corporation | 13 | 2010-11-01 | 2026-06-17 |
| Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer Imetelstat sodium, Bevacizumab, Paclitaxel - Locally Recurrent or Metastatic Breast Cancer | Phase 2 | Completed | Geron Corporation | 166 | 2010-11-01 | 2016-01-26 |
| Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) imetelstat, Bevacizumab - Non-small Cell Lung Cancer | Phase 2 | Completed | Geron Corporation | 116 | 2010-05-01 | 2016-01-26 |
Myelodysplastic Syndromes (3) · Primary Myelofibrosis (2) · Recurrence (2) · Astrocytoma (1) · Brain Stem Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Disease (1) · Ependymoma (1) · Glioblastoma (1) · Gliosarcoma (1) · Hepatoblastoma (1) · Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1) · Myeloproliferative Disorders (1)
Geron Corporation (7) · Children's Oncology Group (1) · GCP-Service International West GmbH (1) · M.D. Anderson Cancer Center (1) · Pediatric Brain Tumor Consortium (1)
United States (9) · Germany (5) · Canada (4) · France (3) · Belgium (2) · Israel (2) · Italy (2) · South Korea (2) · Spain (2) · Switzerland (2) · United Kingdom (2) · Australia (1) · Czechia (1) · Netherlands (1) · Poland (1)
Bravo G Montalban, MD (1) · Carol Ann Huff, M.D. (1) · Joan Schiller, MD (1) · Joe Eid (1) · Kathy Miller, MD (1) · Maryam Fouladi (1) · Patrick Thompson (1) · Ted Shih, PharmD (1) · Tymara Berry, MD (1) · Uwe Platzbecker, MD (1)
PMID 26332545, PMID 26332546, PMID 32732354, PMID 33108243, PMID 34138638, PMID 38048786, PMID 41135032, PMID 41568521
2015 (2), U01CA081457 (1), U10CA098543 (1)